View Filing Data

Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Dec. 31, 2018	Mar. 07, 2019	Jun. 30, 2018
Document and Entity Information [Abstract]
Entity Registrant Name	OptimizeRx Corp
Entity Central Index Key	0001448431
Trading Symbol	OPRX
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Type	10-K
Document Period End Date	Dec. 31, 2018
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2018
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Shell Company	false
Entity Ex Transition Period	false
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Public Float			$ 81,729,898
Entity Common Stock, Shares Outstanding		12,095,111

Consolidated Balance Sheets - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Current Assets
Cash and cash equivalents	$ 8,914,034	$ 5,122,573
Accounts receivable	6,457,841	3,430,890
Prepaid expenses	590,744	255,428
Total Current Assets	15,962,619	8,808,891
Property and equipment, net	149,330	167,305
Other Assets
Goodwill	3,678,513
Patent rights, net	2,766,944	638,766
Other intangible assets, net	2,492,123	143,730
Security deposit	5,049	5,049
Total Other Assets	8,942,629	787,545
TOTAL ASSETS	25,054,578	9,763,741
Current Liabilities
Accounts payable - trade	411,010	457,289
Accrued expenses	1,300,882	953,947
Revenue share payable	1,908,616	1,624,806
Deferred revenue	610,625	507,160
Total Current Liabilities	4,231,133	3,543,202
Non-current Liabilities
Contingent purchase price payable	2,365,000
Total Liabilities	6,596,133	3,543,202
Stockholders' Equity
Preferred stock, $0.001 par value, 10,000,000 shares authorized, no issued and outstanding at December 31, 2018 and 2017,
Common stock, $0.001 par value, 500,000,000 shares authorized, 12,038,618 and 9,772,694 shares issued and outstanding at December 31, 2018 and 2017, respectively	12,039	9,773
Stock warrants		1,286,424
Additional paid-in-capital	48,725,211	35,287,464
Accumulated deficit	(30,278,805)	(30,363,122)
Total Stockholders' Equity	18,458,445	6,220,539
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 25,054,578	$ 9,763,741

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2018	Dec. 31, 2017
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	12,038,618	9,772,694
Common stock, shares outstanding	12,038,618	9,772,694

Consolidated Statements of Operations - USD ($)	12 Months Ended
Consolidated Statements of Operations - USD ($)	Dec. 31, 2018	Dec. 31, 2017
NET REVENUE
Revenue	$ 21,206,363	$ 12,127,422
Revenue share expense	8,999,666	6,174,614
Gross Margin	12,206,697	5,952,808
Operating expenses
Stock-based compensation	2,520,852	902,389
Depreciation and amortization	316,502	324,551
Other general and administrative expenses	9,189,211	6,855,834
Total operating expenses	12,026,565	8,082,774
Income (loss) from operations	180,132	(2,129,966)
Other income
Interest income	46,212	25,937
Total other income	46,212	25,937
Income (loss) before provision for income taxes	226,344	(2,104,029)
Provision for income taxes
Net income (loss)	$ 226,344	$ (2,104,029)
Weighted average number of shares outstanding – basic	10,832,209	9,819,753
Weighted average number of shares outstanding - diluted	11,862,991	9,819,753
Net income (loss) per share – basic	$ 0.02	$ (0.21)
Net income (loss) per share - diluted	$ 0.02	$ (0.21)

Consolidated Statement of Stockholders' Equity - USD ($)	Common Stock	Stock Warrants	Additional Paid-in Capital	Accumulated Deficit	Total
Balance at Dec. 31, 2016	$ 9,906	$ 2,294,416	$ 33,766,950	$ (28,259,093)	$ 7,812,179
Balance, shares at Dec. 31, 2016	9,906,289
Issuance of stock options to employees			815,014		815,014
Issuance of common stock: for services	$ 25		87,350		87,375
Issuance of common stock: for services, shares	25,000
Issuance of common stock: for cash
Issuance of common stock: for cash, shares
Issuance of common stock: for options exercised	$ 8		(8)
Issuance of common stock: for options exercised, shares	8,071
Shares redeemed for cash	$ (166)		(389,834)		(390,000)
Shares redeemed for cash, shares	(166,666)
Expiration of Warrants		(1,007,992)	1,007,992
Net loss for the year				(2,104,029)	(2,104,029)
Balance at Dec. 31, 2017	$ 9,773	1,286,424	35,287,464	(30,363,122)	6,220,539
Balance, shares at Dec. 31, 2017	9,772,694
Cumulative effect of change in accounting principle related to revenue recognition				(142,027)	(142,027)
Stock Compensation Expense			1,863,911		1,863,911
Issuance of common stock: for services	$ 51		656,883		656,934
Issuance of common stock: for services, shares	51,494
Issuance of common stock: for cash	$ 1,667		8,162,807		8,164,474
Issuance of common stock: for cash, shares	1,666,669
Issuance of common stock: for options exercised	$ 165		521,105		521,270
Issuance of common stock: for options exercised, shares	165,169
Issuance of common stock: for warrants exercised	$ 251	(1,286,424)	1,286,173
Issuance of common stock: for warrants exercised, shares	251,046
Shares issued for acquisition	$ 31		499,969		$ 500,000
Shares issued for acquisition, shares	30,638				30,638
Shares issued in payment of revenue shares	$ 100		446,900		$ 447,000
Shares issued in payment of revenue share, shares	100,000
Additional shares issued in connection with reverse split due to rounding	$ 1		(1)
Additional shares issued in connection with reverse split due to rounding, shares	908
Net loss for the year				226,344	226,344
Balance at Dec. 31, 2018	$ 12,039		$ 48,725,211	$ (30,278,805)	$ 18,458,445
Balance, shares at Dec. 31, 2018	12,038,618

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
Consolidated Statements of Cash Flows - USD ($)	Dec. 31, 2018	Dec. 31, 2017
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss) for the period	$ 226,344	$ (2,104,029)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation and amortization	316,502	324,551
Loss on disposal of assets	2,401	65,738
Stock issued for services	656,934	815,014
Stock-based compensation	1,863,911	87,375
Changes in:
Accounts receivable	(2,789,252)	(370,494)
Prepaid expenses	(319,754)	(174,608)
Accounts payable	(83,319)	88,075
Revenue share payable	730,810	(997,711)
Accrued expenses	226,535	665,679
Deferred revenue	(38,557)	120,579
NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES	792,555	(1,479,831)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment	(34,362)	(42,243)
Acquisition of intangible assets	(56,651)
Cash paid in acquisition, net of cash acquired	(5,595,820)
NET CASH USED IN INVESTING ACTIVITIES	(5,686,833)	(42,243)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock	8,164,475
Proceeds from exercise of stock options	521,264
Redemption of common stock		(390,000)
NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES	8,685,739	(390,000)
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	3,791,461	(1,912,074)
CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD	5,122,573	7,034,647
CASH AND CASH EQUIVALENTS - END OF PERIOD	8,914,034	5,122,573
SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for interest
Cash paid for income taxes
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Exercise of stock warrants	1,286,424
Common stock issued for debt	477,000
Shares issued in acquisition of CareSpeak	500,000
Effect of ASC 606 revenue recognition	$ 142,027

Organization and Nature of Business

12 Months Ended

Dec. 31, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

ORGANIZATION AND NATURE OF BUSINESS

NOTE 1 – ORGANIZATION AND NATURE OF BUSINESS

OptimizeRx Corporation is a leading provider of digital health messaging via electronic health records (EHRs), providing a direct channel for pharmaceutical companies to communicate with healthcare providers. The Company's cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education and critical clinical information. The Company's network is comprised of leading EHR platforms and provides more than half of the ambulatory patient market with access to these benefits within their workflow at the point-of-care.

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2018

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America and are presented in US dollars. The Company has adopted a December 31^st fiscal year-end.

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates and assumptions have been made in determining the carrying value of assets, depreciable and amortizable lives of tangible and intangible assets, the carrying value of liabilities, the amount of revenue to be billed, and the timing of revenue recognition and related revenue share expenses. Actual results could differ from these estimates.

Principles of Consolidation

The financial statements reflect the consolidated results of OptimizeRx Corporation, a Nevada corporation, and its wholly owned subsidiaries, OptimizeRx Corporation, a Michigan Corporation, CareSpeak Communications, Inc., a New Jersey Corporation, and CareSpeak Communications D.O.O. a Controlled Foreign Corporation incorporated in Croatia. Together, these companies are referred to as “OptimizeRx” and “the Company”. All material intercompany transactions have been eliminated.

Reclassifications

Certain items in the previous year financial statements have been reclassified to match the current year presentation.

Cash and Cash Equivalents

For purposes of the accompanying financial statements, the Company considers all highly liquid instruments with an initial maturity of three months or less to be cash equivalents.

Fair Value of Financial Instruments

Fair value is defined as the price that would be received upon sale of an asset or paid upon transfer of a liability in an orderly transaction between market participants at the measurement date and in the principal or most advantageous market for that asset or liability. The fair value should be calculated based on assumptions that market participants would use in pricing the asset or liability, not on assumptions specific to the entity. In addition, the fair value of liabilities should include consideration of non-performance risk including our own credit risk.

In addition to defining fair value, the disclosure requirements around fair value establish a fair value hierarchy for valuation inputs, which is expanded. The hierarchy prioritizes the inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market. Each fair value measurement is reported in one of the three levels, which is determined by the lowest level input that is significant to the fair value measurement in its entirety. These levels are:

Level 1 – Inputs are based upon unadjusted quoted prices for identical instruments traded in active markets.

Level 2 – Inputs are based upon significant observable inputs other than quoted prices included in Level 1, such as quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 – Inputs are generally unobservable and typically reflect management’s estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are therefore determined using model-based techniques that include option pricing models, discounted cash flow models, and similar techniques. The Company’s stock options and warrants are valued using level 3 inputs.

The following tables present the fair values and carrying values of the Company’s financial assets and liabilities measured on a recurring basis as of December 31, 2018 and 2017 and the valuation techniques used by the Company to determine those fair values.

	2018
	Level 1		Level 2		Level 3		Fair Value		Carrying Value

Liabilities
Contingent Purchase Price Payable (1)	$	-	$	-	$	2,365,000	$	2,365,000	$	2,365,000

(1)

The contingent consideration is based off achieving certain revenue milestones in each of the next two years. The Geometric-Brownian motion analysis was used to generate spot prices for use in an option pricing model. The hypothetical spot prices were simulated using a monte carlo simulation utilizing 2018 revenue as a base and revenue volatility of 37%. The risk-free rate of return and terms utilized were 2.89% and 1.46-2.46, respectively and expected volatility was 35%.

The following table provides a summary of changes in fair value of the Company’s Level 3 financial instruments for the years ended December 31, 2018 and 2017.

	Amount
Balance December 31, 2017	$	-
Contingent consideration liability recorded as the result of the CareSpeak Communications acquisition (see note 3)		2,365,000
Balance December 31, 2018	$	2,365,000

Accounts Receivable and Allowance for Doubtful Accounts

Accounts receivable are reported at realizable value, net of allowances for doubtful accounts, which is estimated and recorded in the period the related revenue is recorded. The Company has a standardized approach to estimate and review the collectability of its receivables based on a number of factors, including the period they have been outstanding. Historical collection and payer reimbursement experience is an integral part of the estimation process related to allowances for doubtful accounts. In addition, the Company regularly assesses the state of its billing operations in order to identify issues, which may impact the collectability of these receivables or reserve estimates. Because the Company’s customers are primarily large well-capitalized companies, historically there has been very little bad debt expense. Bad debt expense was $0 for each of the years ended December 31, 2018 and 2017. The allowance for doubtful accounts was $0 as of both December 31, 2018 and 2017.

Property and Equipment

Property and equipment are stated at cost and are being depreciated over their estimated useful lives of three to five years for office equipment and three years for computer equipment using the straight-line method of depreciation for book purposes. Maintenance and repair charges are expensed as incurred.

Intangible Assets

Intangible assets are stated at cost. Finite-lived assets are being amortized over their estimated useful lives of fifteen to seventeen years for patents, eight years for customer relationships, four years for covenants not to compete, and three to four years for software and websites, all using the straight-line method. These assets, as well as our indefinite-lived asset, are evaluated annually in our fiscal fourth quarter for impairment.

Goodwill

We evaluate goodwill for impairment during our fiscal fourth quarter, or more frequently if an event occurs or circumstances change.

Revenue Recognition

Recognition of revenue requires evidence of a contact, probable collection of proceeds, and completion of substantially all performance obligations. We use a 5-step model to recognize revenue. These steps are: identify the performance obligations in the contract, determine the transaction price, allocate the transaction price to the performance obligations in the contract, and recognize revenue when or as the performance obligations are satisfied.

Revenues are primarily generated from content delivery activities in which the Company delivers financial clinical, or brand messaging through a distribution network of ePrescribers and Electronic Health Record technology providers (channel partners), directly to consumers, or from reselling services that complement the business. Unless otherwise specified, revenue is recognized based on the gross selling price to customers.

The Company’s contracts are generally all less than one year and the primary performance obligation is delivery of the message, but the contract may contain additional performance obligations. Additional performance obligations may include program design and set up, and reporting.

As the messaging is distributed through the platform and network of channel partners (a transaction), these transactions are recorded, and revenue is recognized, at the time of distribution. Revenue for transactions can be realized based on a price per message, a price per redemption, or as a flat fee occurring over a period of time, depending on the client contract. The Company recognizes setup fees that are required for integrating client offerings and campaigns into the rule-based content delivery system and network over the life of the initial program, based either on time, or units delivered, depending upon which is most appropriate in the specific situation. Additionally, the Company also recognizes revenue for providing program performance reporting and maintenance, either by the Company directly delivering reports or by providing access to its online reporting portal that the client can utilize. These fees are charged monthly and recognized as recurring monthly revenue at the time of delivery.

In some instances, the Company also resells products and or services that are available through channel partners on a commission basis, and that are complementary to the core business and client base. In these instances, net revenue is recognized based on the commission based revenue split that the Company receives. In instances where the Company resells services and have all financial risk and significant operation input and risk, the Company records the revenue gross.

Revenue Share Expenses

Based on the volume of transactions that are delivered through the channel partner network, the Company provides a revenue share to compensate the partner for their promotion of the campaign. Revenue shares are a negotiated percentage of the transaction fees and can also be specific to special considerations and campaigns. In addition, the Company pays revenue share to ConnectiveRx (formerly LDM/PDR) as a result of a 2014 legal settlement in an amount equal to the greater of 10% of financial messaging distribution revenues generated through its integrated network, or $0.37 per financial message distributed through its integrated network. The contractual amount due to the channel partners is recorded as an expense at the time the eCoupon is distributed.

Income Taxes

Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax basis of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized.

The Company recognizes the tax benefit from uncertain tax positions if it is more likely than not that the tax positions will be sustained on examination by the tax authorities, based on the technical merits of the position. The tax benefit is measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. It is the Company’s policy to include interest and penalties related to tax positions as a component of income tax expense.

Concentration of Credit Risks

The Company maintains its cash and cash equivalents in bank deposit accounts, which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts; however, amounts in excess of the federally insured limit may be at risk if the bank experiences financial difficulties. As of December 31, 2018, the Company had $8,414,034 in cash balances in excess of federally insured limits, primarily at Bank of America/Merrill Lynch.

Research and Development

The Company expenses research and development expenses as incurred. Our research efforts are focused on understanding the market dynamics that have the potential to affect the business and increase revenue in both the short and long term. Our primary goal is to increase revenue by helping patients better afford and access the medicines their doctors prescribe, as well as other healthcare products and services they need. Based on this, the Company continually seeks ways to improve its technology to enhance user experiences, and to develop new services and solutions for its customers.

Share-based Payments

The Company uses the fair value method to account for stock-based compensation. The fair value of the equity instrument is charged directly to compensation expense and additional paid-in capital over the period during which services are rendered. The fair value of each award is estimated on the date of each grant. For restricted stock, the fair market value is based on the market value of the stock granted on the date of the grant. For options, it is estimated using the Black-Scholes option pricing model that uses the assumptions noted in the following table. Estimated volatilities are based on the historical volatility of the Company’s stock over the same period as the expected term of the options. The expected term of options granted represents the period of time that options granted are expected to be outstanding. The Company uses historical data to estimate option exercise behavior and to determine this term. The risk free rate used is based on the U.S. Treasury yield curve in effect at the time of the grant using a time period equal to the expected option term. The Company has never paid dividends and does not expect to pay any dividends in the future.

	2018			2017

Expected dividend yield		0	%		0	%
Risk free interest rate		1.96% - 2.84	%		1.47% - 1.81	%
Expected option term		3.5 - 5 years			3.5 - 5 years
Turnover/forfeiture rate		0	%		0	%
Expected volatility		64% - 66	%		65% - 78	%

The Black-Scholes option valuation model and other existing models were developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable. These option valuation models require the input of, and are highly sensitive to, subjective assumptions including the expected stock price volatility. The Company’s stock options have characteristics significantly different from those of traded options, and changes in the subjective input assumptions could materially affect the fair value estimate.

Loss Per Common and Common Equivalent Share

The computation of basic earnings per common share is computed using the weighted average number of common shares outstanding during the year. The computation of diluted earnings per common share is based on the basic weighted average number of shares outstanding during the year plus common stock equivalents, which would arise from the exercise of options and warrants outstanding using the treasury stock method and the average market price per share during the year. The number of common shares potentially issuable upon the exercise of certain options and warrants that were excluded from the diluted loss per common share calculation in 2017 was approximately 489,201, because they are anti-dilutive, as a result of a net loss for the year ended December 31, 2017.

The computation of weighted average shares outstanding and the basic and diluted earnings per common share for the year ended December 31, 2018 consisted of the following:

	Net Income		Shares		Per Share Amount
Year ended December 31, 2018:
Basic EPS	$	226,344		10,832,209	$	0.02
Effect of dilutive stock options and warrants				1,030,782

Diluted EPS	$	226,344		11,862,911	$	0.02

Impairment of Long-Lived Assets

The Company continually monitors events and changes in circumstances that could indicate carrying amounts of long-lived assets may not be recoverable. When such events or changes in circumstances are present, the Company assesses the recoverability of long-lived assets by determining whether the carrying value of such assets will be recovered through undiscounted expected future cash flows. If the total of the future cash flows is less than the carrying amount of those assets, the Company recognizes an impairment loss based on the excess of the carrying amount over the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or the fair value less costs to sell.

Recently Issued Accounting Guidance

On January 1, 2018, we adopted the new accounting standard ASC 606, Revenue from Contracts with Customers, and all of the related amendments (“new revenue standard”). We recorded the change, which was immaterial, related to adopting the new revenue standard using the modified retrospective method. Under this method, we recognized the cumulative effect of initially applying the new revenue standard as an adjustment to the opening balance of retained earnings. This results in no restatement of prior periods, which continue to be reported under the accounting standards in effect for those periods. We expect the impact of the adoption of the new revenue standard to continue to be immaterial on an ongoing basis.

We have applied the new revenue standard to all contracts as of the date of initial application. The overwhelming majority of our revenue continues to be recognized when transactions occur, such as the delivery of a message. We previously recognized revenue related to set-ups when a program launched, and all related activities had been accomplished. Under the new revenue standard, we are recognizing revenue related to these set ups over the term of the initial contract. Since set up fees are generally small relative to the size of the overall contract and because most contracts are for a year or less, the impact of this change is immaterial.

The impact of recording this change as of January 1, 2018 resulted in an increase in deferred revenue of $142,027 at that date and a corresponding decrease in retained earnings as well. The impact of adopting the new revenue standard in 2018 resulted in lower revenues of $59,387 than would have been reported under the previous method.

In October 2016, the FASB issued ASC 2016-16 amending the accounting for income taxes, primarily related to intercompany transfers of inventory. We adopted this in 2018 and it had no impact on our financial statements or disclosures.

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) (“ASU 2016-02”), which modifies lease accounting for lessees to increase transparency and comparability by recording lease assets and liabilities for operating leases and disclosing key information about leasing arrangements. The Company will adopt ASU 2016-02 in its first quarter of 2019. While the Company is currently evaluating the timing and impact of adopting ASU 2016-02, currently the Company anticipates no material impact to its Consolidated Statements of Operations.

Acquisition

12 Months Ended

Dec. 31, 2018

Business Combinations [Abstract]

ACQUISITION

NOTE 3 – ACQUISITION

On October 17, 2018, we acquired CareSpeak Communications, Inc., a New Jersey corporation and technology solutions company, which provides digital messaging services to the healthcare industry to expand our service offerings. Through its cloud based Mobile Health Messenger ("MHM") Platform, CareSpeak provides interactive health messaging for improved medication adherence, care coordination, and patient engagement. The total purchase price was $8,493,451. Acquisition costs of approximately $607,670 were expensed as incurred.

The purchase price contains a contingent element that will be paid only if the Company achieves certain patient engagement revenues in 2019 and 2020. The total contingent payment may be up to $3.0 million. The calculated fair value of the contingent payment is $2,365,000 at December 31, 2018.

We began consolidating the results of CareSpeak operations and cashflows into our consolidated financial statements after October 17, 2018, the date of acquisition. The unaudited Pro forma results of operations as if the acquisition occurred January 1, 2017 are presented in the following table:

	2018				2017
	As Reported		Pro Forma		As Reported			Pro Forma
Net Sales	$	21,206,363	$	22,152,995	$	12,127,422		$	12,927,881
Net Income (loss)		226,344		690,492		(2,104,029	)		(2,513,029	)
Earnings per common share:
Basic	$	0.02	$	0.06	$	(0.21	)	$	(0.26	)
Diluted	$	0.02	$	0.06	$	(0.21	)	$	(0.26	)

Purchase Price Allocation

The purchase price of the acquisition was allocated as follows:

Purchase Price
Cash paid	$	5,628,451
Common stock issued		500,000
Contingent payment		2,365,000
Total	$	8,493,451

Allocation
Current assets	$	254,263
Property and equipment		8,487
Intangibles
Goodwill, including assembled workforce in place		3,678,513
Patent		2,227,000
Tradename		982,000
Non-compete agreements		977,000
Customer relationships		492,000
Current liabilities assumed		(125,812	)
Total	$	8,493,451

As described in greater detail in Note 6, the amortizable intangible assets acquired have estimated useful lives ranging from 4 to 15 years. We determined the estimated fair value of the identifiable intangible assets acquired primarily by using the income approach.

Prepaid Expenses

12 Months Ended

Dec. 31, 2018

Prepaid Expenses [Abstract]

PREPAID EXPENSES

NOTE 4 – PREPAID EXPENSES

Prepaid expenses consisted of the following as of December 31, 2018 and 2017:

	2018		2017
Insurance	$	43,284	$	43,764
Rent		1,589		8,539
EHR access fees		533,125		203,125
Other		12,746		-
Total prepaid expenses	$	590,744	$	255,428

Property and Equipment

12 Months Ended

Dec. 31, 2018

Property, Plant and Equipment [Abstract]

PROPERTY AND EQUIPMENT

NOTE 5 – PROPERTY AND EQUIPMENT

The Company owned equipment recorded at cost which consisted of the following as of December 31, 2018 and 2017:

	2018		2017
Computer equipment	$	94,384	$	83,079
Furniture and fixtures		159,648		158,502
Subtotal		254,032		241,581
Less accumulated depreciation		104,702		74,276
Property and equipment, net	$	149,330	$	167,305

Depreciation expense was $58,423 and $48,587 for the years ended December 31, 2018 and 2017, respectively.

Intangible Assets

12 Months Ended

Dec. 31, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

INTANGIBLE ASSETS

NOTE 6 – INTANBIGLE ASSETS

Goodwill

The goodwill is related to the acquisition of CareSpeak Communications in 2018 and is primarily related to expected improvements and technology performance and functionality, as well sales growth from future product and service offerings and new customers, together with certain intangible assets that do not qualify for separate recognition, such as the assembled workforce in place. Goodwill is generally not amortizable for tax purposes and is not amortizable for financial statement purposes.

Intangible Assets

Intangible assets included on the balance sheet consist of the following:

	December 31, 2017
	Gross Carrying Amount		Accumulated Amortization		Net
Patent rights	$	1,102,457	$	463,691	$	638,766
Other intangible assets
Web-Based Technology		1,458,362		1,314,632		143,730
Total other		1,458,362		1,314,632		143,730
Total Intangibles	$	2,560,819	$	1,778,323	$	782,496

	December 31, 2018
	Gross Carrying Amount		Accumulated Amortization		Net		Weighted Average Life Remaining
Patent rights	$	3,329,457	$	562,513	$	2,766,944		12.7
Other intangible assets
Tradename		982,000		-		982,000		Indefinite
Non-compete agreements		977,000		50,885		926,115		3.8
Customer relationships		492,000		12,812		479,188		7.8
Web-based technology		1,515,013		1,410,193		104,820		1.1
Total other		3,966,013		1,473,890		2,492,123
Total Intangibles	$	7,295,470	$	2,036,403	$	5,259,067

Intangibles are being amortized on a straight-line basis over the following estimated useful lives.

Patents			15 - 17 years
Non-compete agreements			4 years
Customer relationships			8 years
Web-based technology			3 years

The Company recorded amortization expense $258,079 and $275,964 in the years ended December 31, 2018 and 2017, respectively. Expected future amortization expenses of the intangibles assets as of December 31, 2018 is as follows:

Year ended December 31,
2019	$	593,682
2020		540,991
2021		536,468
2022		471,222
2023		277,857
Thereafter		1,856,847
Total	$	4,277,067

Deferred Revenue

12 Months Ended

Dec. 31, 2018

Revenue Recognition [Abstract]

DEFERRED REVENUE

NOTE 7 – DEFERRED REVENUE

The Company has several signed contracts with customers for the distribution of financial messaging, or other services, which include payment in advance. The payments are not recorded as revenue until the revenue is earned under its revenue recognition policy discussed in Note 2. Deferred revenue was $610,625 and $507,160 as of December 31, 2018 and 2017, respectively.

Related Party Transactions

12 Months Ended

Dec. 31, 2018

RELATED PARTY TRANSACTIONS

NOTE 8 – RELATED PARTY TRANSACTIONS

During the year ended December 31, 2010, the Company acquired the technical contributions and assignment of all exclusive rights to and for a key patent in process at the time from a former CEO in exchange for a total payment in shares of common stock and options valued at $930,000 at the time, and recorded at that cost. That patent remains in Patents on the consolidated balance sheet as of December 31, 2018.

During the year ended December 31, 2015, WPP, plc made a strategic investment in the Company and owned approximately 20% of the outstanding shares of the Company until December 2018, when it sold the shares. As of December 31, 2018, WPP is no longer a related party, however the transactions between WPP and the Company are set forth in the table below. The Company considers the pharmaceutical companies being represented by WPP agencies to be its customers and it received no preferable pricing from WPP agencies as a result of its related party status.

The following table sets forth the activity between the Company and WPP for the years ended December 31:

	2018		2017
Total billings to WPP Agencies	$	6,217,735	$	3,554,168
Revenue recognized from WPP Agencies	$	6,527,051	$	3,696,214
Accounts receivable from WPP Agencies	$	2,051,532	$	1,173,614
Rebates given to WPP Agencies	$	-	$	33,249
Marketing services purchased from WPP Agencies	$	-	$	54,762
Revenue share expense recorded to WPP Agencies	$	-	$	401,596
Revenue share expenses owed to WPP Agencies	$	-	$	447,670

Contingent Purchase Price

12 Months Ended

Dec. 31, 2018

Commitments and Contingencies Disclosure [Abstract]

CONTINGENT PURCHASE PRICE

NOTE 9 – CONTINGENT PURCHASE PRICE

Our purchase of CareSpeak Communications contains a contingent element that will be paid only if the Company achieves certain patient engagement revenues in 2019 and 2020. The total contingent payment may be up to $3.0 million. The calculated fair value of the contingent payment is $2,365,000 at December 31, 2018. We determined the fair value of the Contingent Purchase Price Payable using a Geometric-Brownian motion analysis of the expected revenue and resulting earnout payment using inputs that include the spot price, a risk free rate of return of return of 2.89%, a term of 2.46 years, and volatility of 35%. Changes in the inputs could result in a different fair value measurement.

Equity

12 Months Ended

Dec. 31, 2018

Equity [Abstract]

EQUITY

NOTE 10 – EQUITY

Preferred Stock

The Company has 10,000,000 shares of preferred stock, $.001 par value per share, authorized as of December 31, 2018. No shares were issued or outstanding in either year presented.

Common Stock

The Company had 500,000,000 shares of common stock, $.001 par value per share, authorized as of December 31, 2018. There were 12,038,618 and 9,772,694 shares of common stock issued and outstanding at December 31, 2018 and 2017, respectively.

Effective May 14, 2018, in connection with our listing on the Nasdaq Capital Market, we implemented a reverse split of our common stock by exchanging each three shares of our common stock for one share. Our financial statements and all equity transactions have been retroactively adjusted to account for the reverse stock split. We elected to round fractional shares up to the nearest whole number rather than redeem them for cash, and as a result we issued 908 additional shares as a result of this rounding.

In 2018, we issued 100,000 shares of common stock to a subsidiary of WPP, one of the world’s largest media companies, and a shareholder at the time, in full payment of all amounts due under a co-marketing agreement that covered certain WPP agencies, whereby we shared a portion of our revenue with those agencies related to new programs through those agencies. The shares were valued at $447,000, the market value of the stock on the date of issuance. The amount due was recorded as a liability in revenue share payable at December 31, 2017.

During 2018, in a private transaction, we issued 1,666,669 shares of our common stock for gross proceeds of $9,000,000. In connection with this transaction, we incurred equity issuance costs of $835,526 related to payments to advisors and legal fees associated with the transaction, resulting in net proceeds to the Company of $8,164,474.

The Company has a Director Compensation plan covering its independent non-employee Directors. A total of 36,494 and 25,000 shares were granted and issued in the years ended December 31, 2018 and 2017, respectively in connection with this compensation plan. These shares were valued at $428,884 and $87,375, respectively. The Company also awarded 130,001 restricted stock awards, valued at 546,007, to executive officers. These awards would vest only if the Company achieved certain stretch revenue goals in 2018 or 2019. It was determined that the goal was achieved as of December 31, 2018, so the entire expense was recognized in 2018, but the shares related to these awards will be issued in 2019.

During 2018, we issued 15,000 shares of our common stock, valued at $228,050, for investor relations services. We also issued 30,638 shares of common stock, valued at $500,000, to the former shareholders of CareSpeak Communications, Inc., in connection with the acquisition of the CareSpeak in 2018.

The entire amount recorded in equity related to stock-based compensation is $1,863,911, including the $1,317,904 discussed in Note 11 below related to options.

During, 2018, we issued 251,046 shares of common stock in connection with the cashless exercise of a warrant to purchase 348,194 shares. We also issued 165,169 shares of common stock and received proceeds of $521,270 in connection with the exercise of options in 2018. In 2017 the Company issued 24,214 shares in connection with the exercise of stock options. The options exercised in 2017 were exercised on a net settled basis and no cash proceeds were received.

We adopted the new accounting standard ASC 606, Revenue from Contracts with Customers, as of January 1, 2018, which resulted in a charge of $142,027 to Retained Earnings on that date.

In 2017, the Company purchased and cancelled 500,000 shares of common stock held by the previous CEO at a price of $0.78 per share for a total payment of $390,000.

Stock Options

12 Months Ended

Dec. 31, 2018

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

STOCK OPTIONS

NOTE 11 – STOCK OPTIONS

The Company sponsors a stock-based incentive compensation plan known as the 2013 Equity Compensation Plan (the "Plan"), which was established by the Board of Directors of the Company in June 2013. A total of 500,000 (post-split) shares were initially reserved for issuance under the Plan. The Plan was amended in 2016 to increase the authorized shares to 1,333,334 shares, again in 2018 to increase the authorized shares to 1,833,334, and again in 2019 to increase the authorized shares to 2,500,000. A total of 1,554,700 shares of common stock underlying options were outstanding at December 31, 2018. The Company had no remaining shares available to grant under the Plan at December 31, 2018.

The Plan allows the Company to grant incentive stock options, non-qualified stock options, stock appreciation rights, or restricted stock. The incentive stock options are exercisable for up to ten years, at an option price per share not less than the fair market value on the date the option is granted. The incentive stock options are limited to persons who are regular full-time employees of the Company at the date of the grant of the option. Non-qualified options may be granted to any person, including, but not limited to, employees, independent agents, consultants and attorneys, who the Company's Board or Compensation Committee believes have contributed, or will contribute, to the success of the Company. Non-qualified options may be issued at option prices of less than fair market value on the date of grant and may be exercisable for up to ten years from date of grant. The option vesting schedule for options granted is determined by the Compensation Committee of the Board of Directors at the time of the grant. The Plan provides for accelerated vesting of unvested options if there is a change in control, as defined in the Plan.

The compensation cost that has been charged against income related to options for the years ended December 31, 2018 and 2017, was $1,317,904 and $815,014, respectively. No income tax benefit was recognized in the income statement and no compensation was capitalized in any of the years presented.

The Company had the following option activity during the years ended December 31, 2018 and 2017:

	Number of Options			Weighted average exercise price		Weighted average remaining contractual life (years)		Aggregate intrinsic value $
Outstanding, January 1, 2017		1,040,022		$	3.36
Granted – 2017		480,417		$	2.88
Exercised – 2017		(43,333	)	$	3.81
Expired – 2017		(108,334	)	$	4.02
Outstanding, December 31, 2017		1,368,772		$	3.12		3.2
Granted – 2018		401,099		$	9.27
Exercised – 2018		(165,169	)	$	3.16
Expired – 2018		(50,002	)	$	5.48
Outstanding, December 31, 2018		1,554,700		$	4.63		3.0	$	10,523,497
Exercisable, December 31, 2018		1,041,533		$	3.34		2.8	$	7,928,828

Of the options outstanding at December 31, 2018, 1,041,533 were exercisable with a weighted average contractual life of 2.8 years and the remaining 513,167 were non-vested.

The table below shows the expiration date and exercise price of the options outstanding at December 31, 2018.

Number of Options			Exercise Price		Expiration Date
	194,666		$	2.46	03/31/22
	20,000		$	3.15	03/17/19
	18,334		$	3.15	05/19/19
	46,668		$	3.15	06/24/20
	235,604		$	3.15	07/27/22
	500,000		$	3.21	02/22/21
	129,169		$	3.45	07/28/21
	5,167		$	3.51	11/01/22
	28,574		$	3.66	03/03/19
	161,675		$	4.20	02/01/23
	15,003		$	4.62	03/31/23
	10,420		$	4.71	12/31/22
	10,420		$	10.40	06/30/23
	16,000		$	12.49	08/13/23
	6,000		$	12.51	08/20/23
	10,000		$	12.70	08/22/23
	15,000		$	12.73	09/04/23
	125,000		$	15.40	10/16/23
	7,000		$	16.24	10/22/23

	Total	1,554,700	$	4.63

There is $1,433,198 of expense remaining to be recognized related to options outstanding at December 31, 2018.

Warrants

12 Months Ended

Dec. 31, 2018

Warrants [Abstract]

WARRANTS

NOTE 12 –WARRANTS

The Company has issued warrants to purchase common stock, primarily in connection with capital raising activities. However, all remaining warrants were exercised in 2018 and there are no remaining warrants outstanding at December 31, 2018.

The Company had the following warrant activity during the years ended December 31, 2018 and 2017:

	Number of Shares Underlying Warrants			Weighted average exercise price
Outstanding, January 1, 2017		681,527		$	5.01
Expired		(333,333	)	$	6.75
Balance, December 31, 2017		348,194		$	3.33
Exercised		(348,194	)	$	3.33
Balance, December 31, 2018		-			-

Major Customers and Vendors

12 Months Ended

Dec. 31, 2018

Major Customers [Abstract]

MAJOR CUSTOMERS AND VENDORS

NOTE 13 – MAJOR CUSTOMERS AND VENDORS

The Company had the following customers that accounted for 10% or greater of revenue in either 2018 or 2017. No other customers accounted for more than 10% of revenue in either year presented.

	2018			2017
		$	%		$	%
Customer A		2,547,113	12.0		957,222	7.9
Customer B		2,280,873	10.8		1,422,072	11.7
Customer C		2,122,657	10.0		1,153,714	9.5

The Company had four key partners through which 10% or greater of its revenue was generated in either 2018 or 2017 as set forth below.

	2018			2017
		$	%		$	%
Partner A		6,841,386	32.3		3,901,811	32.2
Partner B		5,350,393	25.2		2,047,238	16.9
Partner C		2,584,103	12.2		1,231,662	10.2
Partner D		2,159,356	10.2		1,279,321	10.5

Income Taxes

12 Months Ended

Dec. 31, 2018

Income Tax Disclosure [Abstract]

INCOME TAXES

NOTE 14 – INCOME TAXES

As of December 31, 2018, the Company had net operating loss carry forwards of approximately $10.9 million that expire from 2027 through 2037 that are available to offset future taxable income. The Company was formed in 2006 as a limited liability company and changed to a corporation in 2007. Activity prior to incorporation is not reflected in the Company’s corporate tax returns. In the future, the cumulative net operating loss carry-forward for income tax purposes may differ from the cumulative financial statement loss due to timing differences between book and tax reporting.

In 2017, the U.S. enacted the Tax Cuts and Jobs Act which significantly changed U.S. tax law. The Act lowered the U.S. statutory federal income tax rate from 35% to 21% effective January 1, 2018. This had an affect on the value of the Company’s net operating loss carryover, but since the deferred tax asset is fully reserved, it had no impact on the Company’s financial statements. The impact of the change was reflected in the 2017 financial statements.

The provision for Federal income tax consists of the following for the years ended December 31, 2018 and 2017:

	2018			2017
Federal income tax benefit attributable to:
Current operations	$	(48,000	)	$	715,000
Permanent and timing differences (net)		(36,000	)		(280,000	)
Tax rate change		-			(1,600,000	)
Valuation allowance		84,000			1,165,000
Net provision for federal income tax	$	-		$	-

The cumulative tax effect of significant items comprising our net deferred tax amount at the expected rate of 21% is as follows as of December 31, 2018 and 2017:

	2018			2017
Deferred tax asset attributable to:
Net operating loss carryover	$	2,290,000		$	2,551,000
Depreciation and amortization		119,000			98,000
Stock compensation		535,000			372,000
Other		(6,000	)
Valuation allowance		(2,938,000	)		(3,021,000	)
Net deferred tax asset	$	-		$	-

Under certain circumstances issuance of common shares can result in an ownership change under Internal Revenue Code Section 382, which limits the Company’s ability to utilize carry forwards from prior to the ownership change. Any such ownership change resulting from stock issuances and redemptions could limit the Company’s ability to utilize any net operating loss carry forwards or credits generated before this change in ownership. These limitations can limit both the timing of usage of these laws, as well as the loss of the ability to use these net operating losses. It is likely that fundraising activities have resulted in such an ownership change.

Commitments and Contingent Liabilities

12 Months Ended

Dec. 31, 2018

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENT LIABILITIES

NOTE 15 – COMMITMENTS AND CONTINGENT LIABILITIES

Legal

The Company is not involved in any legal proceedings.

Revenue-share contracts

The Company has contacts with various Electronic Health Records systems and ePrescribe platforms, whereby we agree to share a portion of the revenue we generate for eCoupons distributed through their networks. These contracts grant audit rights related to the payments to our partners, and in some cases would require us to pay for the audit if the audit determined there was an underpayment and the underpayment meets certain thresholds, such as 10%.

Operating Leases

The Company initially signed the lease for its current office space located in Rochester Michigan on December 1, 2011. That lease expired on November 30, 2016 and the Company signed a new lease for the same space. The current lease is a three-year lease beginning December 1, 2016, with options for up to an additional 6 years. The rent is payable monthly at rates of $6,232, $6,308, and $6,384 per month for years 1, 2, and 3 of the lease, respectively. The monthly rates for the option years range from $6,384 per month to $6,688 per month for the option years 4 through 9 of the lease. If the Company fails to exercise its option for option years 4 and 5, a lease termination payment of $7,300 will be due at the end of the initial 3-year term.

The Company also has a short-term lease on office space in Somerset, New Jersey expiring March 31, 2018. The lease is a twelve-month lease calling for twelve monthly payments of $700.

The Company also has a short-term lease on an office space in Zagreb, Croatia expiring July 4, 2018. The lease is a twelve-month lease calling for twelve monthly payments approximately $630 USD.

The Company also has a month to month leases on shared office spaces in Nashville, Tennessee, payable at a rate of approximately $2,050 per month.

Minimum annual rent payments are as follows for the remaining term of the leases:

Year ended December 31:
2019		76,104
Total lease commitment	$	76,104

Retirement Plan

12 Months Ended

Dec. 31, 2018

Retirement Benefits [Abstract]

RETIREMENT PLAN

NOTE 16 – RETIREMENT PLAN

The Company sponsors a defined contribution 401(k) profit sharing plan which was adopted in December 2015, effective in January 2016. Under the terms of the plan, the Company matches 100% of the first 3% of payroll contributed by the employee and 50% of the next 2% of payroll contributed by the employee to a maximum of 4% of an employee's payroll. There was expense of $172,107 and $137,858 recorded in 2018 and 2017, respectively, for company contributions to the plan.

Subsequent Events

12 Months Ended

Dec. 31, 2018

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

NOTE 17 – SUBSEQUENT EVENTS

In February 2019, the Company's Board of Directors amended the 2013 Equity Compensation Plan to increase the number of shares authorized under the plan to 2,500,000. At the same time, the Company granted 50,000 shares of restricted common stock to officers and options to purchase 67,050 shares of common stock with an exercise price of $13.06 to non-officers, both of which vest only if the Company achieves certain stretch revenue goals in 2019. In addition, the Company granted 35,500 time-based options, with the same exercise price, to new employees, as well as accelerated vesting to 2019 on 100,000 existing options that previously vested in 2020.

In January 2019, the Company signed a new lease on office space in Cranbury New Jersey commencing on February 1, 2019. The lease is a 3-year lease calling for monthly payments ranging from $2,707 to $2,808 plus utilities during the term of the lease.

In 2019, the company issued 56,493 shares and received proceeds of $228,386 in connection with the exercise of options.

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2018

Accounting Policies [Abstract]

Basis of Presentation

Use of Estimates

Principles of Consolidation

The financial statements reflect the consolidated results of OptimizeRx Corporation, a Nevada corporation, and its wholly owned subsidiaries, OptimizeRx Corporation, a Michigan Corporation, CareSpeak Communications, Inc., a New Jersey Corporation, and CareSpeak Communications D.O.O. a Controlled Foreign Corporation incorporated in Croatia. Together, these companies are referred to as "OptimizeRx" and "the Company". All material intercompany transactions have been eliminated.

Reclassifications

Certain items in the previous year financial statements have been reclassified to match the current year presentation.

Cash and Cash Equivalents

For purposes of the accompanying financial statements, the Company considers all highly liquid instruments with an initial maturity of three months or less to be cash equivalents.

Fair Value of Financial Instruments

Level 1 – Inputs are based upon unadjusted quoted prices for identical instruments traded in active markets.

Level 3 – Inputs are generally unobservable and typically reflect management's estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are therefore determined using model-based techniques that include option pricing models, discounted cash flow models, and similar techniques. The Company's stock options and warrants are valued using level 3 inputs.

The following tables present the fair values and carrying values of the Company's financial assets and liabilities measured on a recurring basis as of December 31, 2018 and 2017 and the valuation techniques used by the Company to determine those fair values.

	2018
	Level 1		Level 2		Level 3		Fair Value		Carrying Value

Liabilities
Contingent Purchase Price Payable (1)	$	-	$	-	$	2,365,000	$	2,365,000	$	2,365,000

(1)

The following table provides a summary of changes in fair value of the Company's Level 3 financial instruments for the years ended December 31, 2018 and 2017.

	Amount
Balance December 31, 2017	$	-
Contingent consideration liability recorded as the result of the CareSpeak Communications acquisition (see note 3)		2,365,000
Balance December 31, 2018	$	2,365,000

Accounts Receivable and Allowance for Doubtful Accounts

Accounts receivable are reported at realizable value, net of allowances for doubtful accounts, which is estimated and recorded in the period the related revenue is recorded. The Company has a standardized approach to estimate and review the collectability of its receivables based on a number of factors, including the period they have been outstanding. Historical collection and payer reimbursement experience is an integral part of the estimation process related to allowances for doubtful accounts. In addition, the Company regularly assesses the state of its billing operations in order to identify issues, which may impact the collectability of these receivables or reserve estimates. Because the Company's customers are primarily large well-capitalized companies, historically there has been very little bad debt expense. Bad debt expense was $0 for each of the years ended December 31, 2018 and 2017. The allowance for doubtful accounts was $0 as of both December 31, 2018 and 2017.

Property and Equipment

Intangible Assets

Goodwill

We evaluate goodwill for impairment during our fiscal fourth quarter, or more frequently if an event occurs or circumstances change.

Revenue Recognition

The Company's contracts are generally all less than one year and the primary performance obligation is delivery of the message, but the contract may contain additional performance obligations. Additional performance obligations may include program design and set up, and reporting.

Revenue Share Expense

Revenue Share Expenses

Income Taxes

The Company recognizes the tax benefit from uncertain tax positions if it is more likely than not that the tax positions will be sustained on examination by the tax authorities, based on the technical merits of the position. The tax benefit is measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. It is the Company's policy to include interest and penalties related to tax positions as a component of income tax expense.

Concentration of Credit Risks

Research and Development

Share-based Payments

The Company uses the fair value method to account for stock-based compensation. The fair value of the equity instrument is charged directly to compensation expense and additional paid-in capital over the period during which services are rendered. The fair value of each award is estimated on the date of each grant. For restricted stock, the fair market value is based on the market value of the stock granted on the date of the grant. For options, it is estimated using the Black-Scholes option pricing model that uses the assumptions noted in the following table. Estimated volatilities are based on the historical volatility of the Company's stock over the same period as the expected term of the options. The expected term of options granted represents the period of time that options granted are expected to be outstanding. The Company uses historical data to estimate option exercise behavior and to determine this term. The risk free rate used is based on the U.S. Treasury yield curve in effect at the time of the grant using a time period equal to the expected option term. The Company has never paid dividends and does not expect to pay any dividends in the future.

	2018			2017

Expected dividend yield		0	%		0	%
Risk free interest rate		1.96% - 2.84	%		1.47% - 1.81	%
Expected option term		3.5 - 5 years			3.5 - 5 years
Turnover/forfeiture rate		0	%		0	%
Expected volatility		64% - 66	%		65% - 78	%

The Black-Scholes option valuation model and other existing models were developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable. These option valuation models require the input of, and are highly sensitive to, subjective assumptions including the expected stock price volatility. The Company's stock options have characteristics significantly different from those of traded options, and changes in the subjective input assumptions could materially affect the fair value estimate.

Loss Per Common and Common Equivalent Share

The computation of weighted average shares outstanding and the basic and diluted earnings per common share for the year ended December 31, 2018 consisted of the following:

	Net Income		Shares		Per Share Amount
Year ended December 31, 2018:
Basic EPS	$	226,344		10,832,209	$	0.02
Effect of dilutive stock options and warrants				1,030,782

Diluted EPS	$	226,344		11,862,911	$	0.02

Impairment of Long-Lived Assets

Recently Issued Accounting Guidance

On January 1, 2018, we adopted the new accounting standard ASC 606, Revenue from Contracts with Customers, and all of the related amendments ("new revenue standard"). We recorded the change, which was immaterial, related to adopting the new revenue standard using the modified retrospective method. Under this method, we recognized the cumulative effect of initially applying the new revenue standard as an adjustment to the opening balance of retained earnings. This results in no restatement of prior periods, which continue to be reported under the accounting standards in effect for those periods. We expect the impact of the adoption of the new revenue standard to continue to be immaterial on an ongoing basis.

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) ("ASU 2016-02"), which modifies lease accounting for lessees to increase transparency and comparability by recording lease assets and liabilities for operating leases and disclosing key information about leasing arrangements. The Company will adopt ASU 2016-02 in its first quarter of 2019. While the Company is currently evaluating the timing and impact of adopting ASU 2016-02, currently the Company anticipates no material impact to its Consolidated Statements of Operations.

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2018

Accounting Policies [Abstract]

Schedule of financial assets and liabilities measured on a recurring basis

	2018
	Level 1		Level 2		Level 3		Fair Value		Carrying Value

Liabilities
Contingent Purchase Price Payable (1)	$	-	$	-	$	2,365,000	$	2,365,000	$	2,365,000

(1)

Schedule of changes in fair value of the Company’s Level 3 financial instruments

	Amount
Balance December 31, 2017	$	-
Contingent consideration liability recorded as the result of the CareSpeak Communications acquisition (see note 3)		2,365,000
Balance December 31, 2018	$	2,365,000

Schedule of expected dividends

	2018			2017

Expected dividend yield		0	%		0	%
Risk free interest rate		1.96% - 2.84	%		1.47% - 1.81	%
Expected option term		3.5 - 5 years			3.5 - 5 years
Turnover/forfeiture rate		0	%		0	%
Expected volatility		64% - 66	%		65% - 78	%

Schedule of weighted average shares outstanding and the basic and diluted earnings per common share

	Net Income		Shares		Per Share Amount
Year ended December 31, 2018:
Basic EPS	$	226,344		10,832,209	$	0.02
Effect of dilutive stock options and warrants				1,030,782

Diluted EPS	$	226,344		11,862,911	$	0.02

Acquisition (Tables)

12 Months Ended

Dec. 31, 2018

Business Combinations [Abstract]

Schedule of pro forma results of operations

	2018				2017
	As Reported		Pro Forma		As Reported			Pro Forma
Net Sales	$	21,206,363	$	22,152,995	$	12,127,422		$	12,927,881
Net Income (loss)		226,344		690,492		(2,104,029	)		(2,513,029	)
Earnings per common share:
Basic	$	0.02	$	0.06	$	(0.21	)	$	(0.26	)
Diluted	$	0.02	$	0.06	$	(0.21	)	$	(0.26	)

Schedule of purchase price of the acquisition

Purchase Price
Cash paid	$	5,628,451
Common stock issued		500,000
Contingent payment		2,365,000
Total	$	8,493,451

Allocation
Current assets	$	254,263
Property and equipment		8,487
Intangibles
Goodwill, including assembled workforce in place		3,678,513
Patent		2,227,000
Tradename		982,000
Non-compete agreements		977,000
Customer relationships		492,000
Current liabilities assumed		(125,812	)
Total	$	8,493,451

Prepaid Expenses (Tables)

12 Months Ended

Dec. 31, 2018

Prepaid Expenses [Abstract]

Schedule of prepaid expenses

	2018		2017
Insurance	$	43,284	$	43,764
Rent		1,589		8,539
EHR access fees		533,125		203,125
Other		12,746		-
Total prepaid expenses	$	590,744	$	255,428

Property and Equipment (Tables)

12 Months Ended

Dec. 31, 2018

Property, Plant and Equipment [Abstract]

Schedule of property and equipment

	2018		2017
Computer equipment	$	94,384	$	83,079
Furniture and fixtures		159,648		158,502
Subtotal		254,032		241,581
Less accumulated depreciation		104,702		74,276
Property and equipment, net	$	149,330	$	167,305

Intangible Assets (Tables)

12 Months Ended

Dec. 31, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of intangible assets

	December 31, 2017
	Gross Carrying Amount		Accumulated Amortization		Net
Patent rights	$	1,102,457	$	463,691	$	638,766
Other intangible assets
Web-Based Technology		1,458,362		1,314,632		143,730
Total other		1,458,362		1,314,632		143,730
Total Intangibles	$	2,560,819	$	1,778,323	$	782,496

	December 31, 2018
	Gross Carrying Amount		Accumulated Amortization		Net		Weighted Average Life Remaining
Patent rights	$	3,329,457	$	562,513	$	2,766,944		12.7
Other intangible assets
Tradename		982,000		-		982,000		Indefinite
Non-compete agreements		977,000		50,885		926,115		3.8
Customer relationships		492,000		12,812		479,188		7.8
Web-based technology		1,515,013		1,410,193		104,820		1.1
Total other		3,966,013		1,473,890		2,492,123
Total Intangibles	$	7,295,470	$	2,036,403	$	5,259,067

Schedule of intangibles estimated useful lives

Patents			15 - 17 years
Non-compete agreements			4 years
Customer relationships			8 years
Web-based technology			3 years

Schedule of future amortization expenses of intangibles assets

Year ended December 31,
2019	$	593,682
2020		540,991
2021		536,468
2022		471,222
2023		277,857
Thereafter		1,856,847
Total	$	4,277,067

Related Party Transactions (Tables)

12 Months Ended

Dec. 31, 2018

Schedule of sets forth the activity between the Company and WPP

	2018		2017
Total billings to WPP Agencies	$	6,217,735	$	3,554,168
Revenue recognized from WPP Agencies	$	6,527,051	$	3,696,214
Accounts receivable from WPP Agencies	$	2,051,532	$	1,173,614
Rebates given to WPP Agencies	$	-	$	33,249
Marketing services purchased from WPP Agencies	$	-	$	54,762
Revenue share expense recorded to WPP Agencies	$	-	$	401,596
Revenue share expenses owed to WPP Agencies	$	-	$	447,670

Stock Options (Tables)

12 Months Ended

Dec. 31, 2018

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of option activity

	Number of Options			Weighted average exercise price		Weighted average remaining contractual life (years)		Aggregate intrinsic value $
Outstanding, January 1, 2017		1,040,022		$	3.36
Granted – 2017		480,417		$	2.88
Exercised – 2017		(43,333	)	$	3.81
Expired – 2017		(108,334	)	$	4.02
Outstanding, December 31, 2017		1,368,772		$	3.12		3.2
Granted – 2018		401,099		$	9.27
Exercised – 2018		(165,169	)	$	3.16
Expired – 2018		(50,002	)	$	5.48
Outstanding, December 31, 2018		1,554,700		$	4.63		3.0	$	10,523,497
Exercisable, December 31, 2018		1,041,533		$	3.34		2.8	$	7,928,828

Schedule of expiration date and exercise price of the options outstanding

Number of Options			Exercise Price		Expiration Date
	194,666		$	2.46	03/31/22
	20,000		$	3.15	03/17/19
	18,334		$	3.15	05/19/19
	46,668		$	3.15	06/24/20
	235,604		$	3.15	07/27/22
	500,000		$	3.21	02/22/21
	129,169		$	3.45	07/28/21
	5,167		$	3.51	11/01/22
	28,574		$	3.66	03/03/19
	161,675		$	4.20	02/01/23
	15,003		$	4.62	03/31/23
	10,420		$	4.71	12/31/22
	10,420		$	10.40	06/30/23
	16,000		$	12.49	08/13/23
	6,000		$	12.51	08/20/23
	10,000		$	12.70	08/22/23
	15,000		$	12.73	09/04/23
	125,000		$	15.40	10/16/23
	7,000		$	16.24	10/22/23

	Total	1,554,700	$	4.63

Warrants (Tables)

12 Months Ended

Dec. 31, 2018

Warrants [Abstract]

Schedule of warrant activity

	Number of Shares Underlying Warrants			Weighted average exercise price
Outstanding, January 1, 2017		681,527		$	5.01
Expired		(333,333	)	$	6.75
Balance, December 31, 2017		348,194		$	3.33
Exercised		(348,194	)	$	3.33
Balance, December 31, 2018		-			-

Major Customers and Vendors (Tables)

12 Months Ended

Dec. 31, 2018

Customers [Member]

Schedule of accounted percentage of revenue

	2018			2017
		$	%		$	%
Customer A		2,547,113	12.0		957,222	7.9
Customer B		2,280,873	10.8		1,422,072	11.7
Customer C		2,122,657	10.0		1,153,714	9.5

Key Partners [Member]

Schedule of accounted percentage of revenue

	2018			2017
		$	%		$	%
Partner A		6,841,386	32.3		3,901,811	32.2
Partner B		5,350,393	25.2		2,047,238	16.9
Partner C		2,584,103	12.2		1,231,662	10.2
Partner D		2,159,356	10.2		1,279,321	10.5

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2018

Income Tax Disclosure [Abstract]

Schedule of federal income tax benefit

	2018			2017
Federal income tax benefit attributable to:
Current operations	$	(48,000	)	$	715,000
Permanent and timing differences (net)		(36,000	)		(280,000	)
Tax rate change		-			(1,600,000	)
Valuation allowance		84,000			1,165,000
Net provision for federal income tax	$	-		$	-

Schedule of deferred tax assets

	2018			2017
Deferred tax asset attributable to:
Net operating loss carryover	$	2,290,000		$	2,551,000
Depreciation and amortization		119,000			98,000
Stock compensation		535,000			372,000
Other		(6,000	)
Valuation allowance		(2,938,000	)		(3,021,000	)
Net deferred tax asset	$	-		$	-

Commitments and Contingent Liabilities (Tables)

12 Months Ended

Dec. 31, 2018

Commitments and Contingencies Disclosure [Abstract]

Schedule of minimum annual rent payments

Year ended December 31:
2019		76,104
Total lease commitment	$	76,104

Summary of Significant Accounting Policies (Details)

Dec. 31, 2018

USD ($)

^[1]

Liabilities

Contingent Purchase Price Payable

$ 2,365,000

Fair Value, Measurements, Recurring [Member]

Liabilities

Contingent Purchase Price Payable

2,365,000

Fair Value Inputs Level 1 [Member] | Fair Value, Measurements, Recurring [Member]

Liabilities

Contingent Purchase Price Payable

Fair Value, Inputs, Level 2 [Member] | Fair Value, Measurements, Recurring [Member]

Liabilities

Contingent Purchase Price Payable

Fair Value, Inputs, Level 3 [Member] | Fair Value, Measurements, Recurring [Member]

Liabilities

Contingent Purchase Price Payable

$ 2,365,000

[1]

Summary of Significant Accounting Policies (Details 1) - Fair Value, Inputs, Level 3 [Member]	12 Months Ended
	Dec. 31, 2018 USD ($)
Summary Of Significant Accounting Policies [Line Items]
Balance
Contingent consideration liability recorded as the result of the CareSpeak Communications acquisition (see note 3)	2,365,000
Balance	$ 2,365,000

Summary of Significant Accounting Policies (Details 2)	12 Months Ended
Summary of Significant Accounting Policies (Details 2)	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology
Expected dividend yield	0.00%	0.00%
Risk free interest rate minimum	1.96%	1.47%
Risk free interest rate maximum	2.84%	1.81%
Turnover/forfeiture rate	0.00%	0.00%
Expected volatility minimum	64.00%	65.00%
Expected volatility maximum	66.00%	78.00%
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology
Expected option term	5 years	5 years
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology
Expected option term	3 years 6 months	3 years 6 months

Summary of Significant Accounting Policies (Details 3) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Accounting Policies [Abstract]
Basic EPS, Net Income	$ 226,344
Diluted EPS, Net Income	$ 226,344
Basic EPS, Shares	10,832,209	9,819,753
Effect of dilutive stock options and warrants, shares	1,030,782
Diluted EPS, Shares	11,862,991	9,819,753
Basic EPS, Per Share Amount	$ 0.02	$ (0.21)
Diluted EPS, Per Share Amount	$ 0.02	$ (0.21)

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=109256448&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1252-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=109260490&loc=SL5780133-109256

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=109256448&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=109260490&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

+ Details

Summary of Significant Accounting Policies (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Summary Of Significant Accounting Policies [Line Items]
Bad debt expense	$ 0	$ 0
Allowance for doubtful accounts	$ 0	$ 0
Revenue recognition, description	Legal settlement in an amount equal to the greater of 10% of financial messaging distribution revenues generated through the its integrated network, or $0.37 per financial message distributed.
Number of common shares potentially issuable upon the exercise of certain options and warrants		489,201
Cash balances for insured limits	$ 8,414,034
Increase in deferred revenue	(142,027)
Lower revenues	$ 59,387
Contingent consideration, description	The hypothetical spot prices were simulated using a monte carlo simulation utilizing 2018 revenue as a base and revenue volatility of 37%. The risk-free rate of return and terms utilized were 2.89% and 1.46-2.46, respectively and expected volatility was 35%.
Percentage of realized upon ultimate settlement	50.00%
Patents [Member]
Summary Of Significant Accounting Policies [Line Items]
Intangible assets amortized over their estimated useful lives	12 years 8 months 12 days
Customer Relationships [Member]
Summary Of Significant Accounting Policies [Line Items]
Intangible assets amortized over their estimated useful lives	8 years
Covenants [Member]
Summary Of Significant Accounting Policies [Line Items]
Intangible assets amortized over their estimated useful lives	4 years
Minimum [Member] \| Software and Websites [Member]
Summary Of Significant Accounting Policies [Line Items]
Intangible assets amortized over their estimated useful lives	3 years
Minimum [Member] \| Patents [Member]
Summary Of Significant Accounting Policies [Line Items]
Intangible assets amortized over their estimated useful lives	15 years
Maximum [Member] \| Software and Websites [Member]
Summary Of Significant Accounting Policies [Line Items]
Intangible assets amortized over their estimated useful lives	4 years
Maximum [Member] \| Patents [Member]
Summary Of Significant Accounting Policies [Line Items]
Intangible assets amortized over their estimated useful lives	17 years
Computer Equipment [Member]
Summary Of Significant Accounting Policies [Line Items]
Property and equipment, estimated useful lives	3 years
Office Equipment [Member] \| Minimum [Member]
Summary Of Significant Accounting Policies [Line Items]
Property and equipment, estimated useful lives	3 years
Office Equipment [Member] \| Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Property and equipment, estimated useful lives	5 years

Acquisition (Details) - USD ($)	12 Months Ended
Acquisition (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Net Sales	$ 21,206,363	$ 12,127,422
Net Income (loss)	$ 226,344	$ (2,104,029)
Earnings per common share:
Basic	$ 0.02	$ (0.21)
Diluted	$ 0.02	$ (0.21)
Pro Forma [Member]
Net Sales	$ 22,152,995	$ 12,927,881
Net Income (loss)	$ 690,492	$ (2,513,029)
Earnings per common share:
Basic	$ 0.06	$ (0.26)
Diluted	$ 0.06	$ (0.26)

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

Acquisition (Details 1)	1 Months Ended
Acquisition (Details 1)	Oct. 17, 2018 USD ($)
Cash paid	$ 5,628,451
Common stock issued	500,000
Contingent payment	2,365,000
Total	8,493,451
Current assets	254,263
Property and equipment	8,487
Current liabilities assumed	(125,812)
Total	8,493,451
Goodwill [Member]
Intangibles	3,678,513
Patent [Member]
Intangibles	2,227,000
Trade Name [Member]
Intangibles	982,000
Non-compete Agreements [Member]
Intangibles	977,000
Customer relationships [Member]
Intangibles	$ 492,000

Acquisition (Details Textual) - USD ($)	1 Months Ended	12 Months Ended
Acquisition (Details Textual) - USD ($)	Oct. 17, 2018	Dec. 31, 2018
Acquisition (Textual)
Total purchase price	$ 8,493,451
Acquisition costs	$ 607,670
Total contingent payment		$ 3,000,000
Fair value of contingent payment		$ 2,365,000
Estimated useful lives, description		Estimated useful lives ranging from 4 to 15 years.

Prepaid Expenses (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Prepaid Expenses [Abstract]
Insurance	$ 43,284	$ 43,764
Rent	1,589	8,539
EHR access fees	533,125	203,125
Legal	12,746
Total prepaid expenses	$ 590,744	$ 255,428

Property and Equipment (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Property, Plant and Equipment [Line Items]
Property and equipment, Subtotal	$ 254,032	$ 241,581
Less accumulated depreciation	104,702	74,276
Property and equipment, net	149,330	167,305
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Subtotal	94,384	83,079
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Subtotal	$ 159,648	$ 158,502

Property and Equipment (Details Textual) - USD ($)	12 Months Ended
Property and Equipment (Details Textual) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Property and Equipment (Textual)
Depreciation expense	$ 58,423	$ 48,587

Intangible Assets (Details) - USD ($)	12 Months Ended
Intangible Assets (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Finite-Lived Intangible Assets [Line Items]
Intangible assets, Gross Carrying Amount	$ 7,295,470	$ 2,560,819
Accumulated Amortization	2,036,403	1,778,323
Intangible assets , Net	2,766,944	638,766
Web-Based Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, Gross Carrying Amount	1,515,013	1,458,362
Accumulated Amortization	1,410,193	1,314,632
Intangible assets , Net	$ 104,820	143,730
Weighted Average Life Remaining	1 year 1 month 6 days
Patent rights [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, Gross Carrying Amount	$ 3,329,457	1,102,457
Accumulated Amortization	562,513	463,691
Intangible assets , Net	$ 2,766,944	638,766
Weighted Average Life Remaining	12 years 8 months 12 days
Other intangible assets [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, Gross Carrying Amount	$ 3,966,013	1,458,362
Accumulated Amortization	1,473,890	1,314,632
Intangible assets , Net	2,492,123	$ 143,730
Tradename [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, Gross Carrying Amount	982,000
Accumulated Amortization
Intangible assets , Net	982,000
Non-compete agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, Gross Carrying Amount	977,000
Accumulated Amortization	50,885
Intangible assets , Net	$ 926,115
Weighted Average Life Remaining	3 years 9 months 18 days
Customer relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, Gross Carrying Amount	$ 492,000
Accumulated Amortization	12,812
Intangible assets , Net	$ 479,188
Weighted Average Life Remaining	8 years

Intangible Assets (Details 1)	12 Months Ended
Intangible Assets (Details 1)	Dec. 31, 2018
Patents [Member] \| Maximum [Member]
Intangibles amortized estimated useful lives	17 years
Patents [Member] \| Minimum [Member]
Intangibles amortized estimated useful lives	15 years
Non-compete agreements [Member]
Intangibles amortized estimated useful lives	4 years
Customer relationships [Member]
Intangibles amortized estimated useful lives	8 years
Web-based technology [Member]
Intangibles amortized estimated useful lives	3 years

Intangible Assets (Details 2) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Year ended December 31,
2019	$ 593,682
2020	540,991
2021	536,468
2022	471,222
2023	277,857
Thereafter	1,856,847
Total	$ 2,766,944	$ 638,766

Intangible Assets (Details Textual) - USD ($)	12 Months Ended
Intangible Assets (Details Textual) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Intangible Assets (Textual)
Amortization expense	$ 258,079	$ 275,964

Deferred Revenue (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Deferred Revenue (Textual)
Deferred revenue	$ 610,625	$ 507,160

Related Party Transactions (Details) - USD ($)	12 Months Ended
Related Party Transactions (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Revenue recognized from WPP Agencies [Member]
Related Party Transaction [Line Items]
Related party transactions	$ 6,527,051	$ 3,696,214
Revenue share expense recorded to WPP Agencies [Member]
Related Party Transaction [Line Items]
Related party transactions		401,596
Marketing services purchased from WPP Agencies [Member]
Related Party Transaction [Line Items]
Related party transactions		54,762
Rebates given to WPP Agencies [Member]
Related Party Transaction [Line Items]
Related party transactions		33,249
Total billings to WPP Agencies [Member]
Related Party Transaction [Line Items]
Related party transactions	6,217,735	3,554,168
Accounts receivable from WPP Agencies [Member]
Related Party Transaction [Line Items]
Related party transactions	2,051,532	1,173,614
Revenue share expenses owed to WPP Agencies
Related Party Transaction [Line Items]
Related party transactions		$ 447,670

Related Party Transactions (Details Textual) - Chief Executive Officer [Member] - USD ($)	12 Months Ended
	Dec. 31, 2010	Dec. 31, 2015
Related Party Transactions (Textual)
Common stock options	$ 930,000
Percentage of ownership by WPP		20.00%

Contingent Purchase Price (Details) - USD ($)	12 Months Ended
Contingent Purchase Price (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Contingent Purchase Price (Textual)
Contingent purchase price payable	$ 2,365,000
Risk free rate of return	2.89%
Fair value of term	2 years 5 months 16 days
Fair value of volatility	35.00%
Total contingent payment	$ 300,000

Equity (Details) - USD ($)		12 Months Ended
Equity (Details) - USD ($)	May 14, 2018	Dec. 31, 2018	Dec. 31, 2017
Equity (Textual)
Preferred stock, shares authorized		10,000,000	10,000,000
Preferred Stock, par value		$ 0.001	$ 0.001
Preferred stock, shares issued
Preferred stock, shares outstanding
Shares of common stock issued, value		$ 8,164,474
Payments to advisors and legal fees		835,526
Net proceeds issuance of common stock		8,164,474
Common stock value issued for services		656,934	$ 87,375
Common stock acquisition, value		$ 500,000
Common stock acquisition, shares		30,638
Issued shares of common stock in connection with cashless exercise		251,046
Warrant to purchase shares		348,194
Effect of ASC 606 revenue recognition		$ 142,027
Stock-based compensation		1,863,911	87,375
Compensation cost		$ 1,317,904	$ 815,014
Issuance of common stock exercise		165,169	24,214
Issuance of common stock exercise value		$ 521,270
Reserve stock split, description	We implemented a reverse split of our common stock by exchanging each three shares of our common stock for one share.
Shares issued	908
Restricted stock awards value		$ 546,007
Restricted stock awards shares		130,001
Common stock, par value		$ 0.001	$ 0.001
Common stock, shares authorized		500,000,000	500,000,000
Common stock, shares issued		12,038,618	9,772,694
Common stock, shares outstanding		12,038,618	9,772,694
Chief Executive Officer [Member]
Equity (Textual)
Total payment			$ 390,000
Per share price			$ 0.78
Purchased and cancelled shares			500,000
Subsidiary of WPP [Member]
Equity (Textual)
Shares of common stock issued		100,000
Shares of common stock issued, value		$ 447,000
Directors [Member]
Equity (Textual)
Shares of common stock issued, value		$ 428,884	$ 87,375
Compensation plan issuance of shares		36,494	25,000
Investor [Member]
Equity (Textual)
Common stock value issued for services		$ 228,050
Common stock shares issued for services, shares		15,000
Private Transaction [Member]
Equity (Textual)
Shares of common stock issued		1,666,669
Gross proceeds of common stock amount		$ 9,000,000

Stock Options (Details) - Stock Options [Member] - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Number of Options
Begining balance, Outstanding	1,368,772	1,040,022
Granted	401,099	480,417
Exercised	(165,169)	(43,333)
Expired	(50,002)	(108,334)
Ending balance, Outstanding	1,554,700	1,368,772
Exercisable	1,041,533
Weighted average exercise price
Beginning balance, Outstanding	$ 3.12	$ 3.36
Granted	9.27	2.88
Exercised	3.16	3.81
Expired	5.48	4.02
Ending balance, Outstanding	4.63	$ 3.12
Exercisable	$ 3.34
Weighted average remaining contractual life (years)	3 years	3 years 2 months 12 days
Weighted average remaining contractual life (years)	2 years 9 months 18 days
Outstanding, Aggregate intrinsic value	$ 10,523,497
Exercisable, Aggregate intrinsic value	$ 7,928,828

Stock Options (Details 1)	12 Months Ended
Stock Options (Details 1)	Dec. 31, 2018 $ / shares shares
Options One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options \| shares	194,666
Exercise Price \| $ / shares	$ 2.46
Expiration Date	Mar. 31, 2022
Options Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options \| shares	20,000
Exercise Price \| $ / shares	$ 3.15
Expiration Date	Mar. 17, 2019
Options Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options \| shares	18,334
Exercise Price \| $ / shares	$ 3.15
Expiration Date	May 19, 2019
Options Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options \| shares	46,668
Exercise Price \| $ / shares	$ 3.15
Expiration Date	Jun. 24, 2020
Options Five [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options \| shares	235,604
Exercise Price \| $ / shares	$ 3.15
Expiration Date	Jul. 27, 2022
Options Six [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options \| shares	500,000
Exercise Price \| $ / shares	$ 3.21
Expiration Date	Feb. 22, 2021
Options Seven [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options \| shares	129,169
Exercise Price \| $ / shares	$ 3.45
Expiration Date	Jul. 28, 2021
Options Eight [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options \| shares	5,167
Exercise Price \| $ / shares	$ 3.51
Expiration Date	Nov. 01, 2022
Options Nine [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options \| shares	28,574
Exercise Price \| $ / shares	$ 3.66
Expiration Date	Mar. 03, 2019
Options Ten [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options \| shares	161,675
Exercise Price \| $ / shares	$ 4.20
Expiration Date	Feb. 01, 2023
Options Eleven [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options \| shares	15,003
Exercise Price \| $ / shares	$ 4.62
Expiration Date	Mar. 31, 2023
Options Twelve [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options \| shares	10,420
Exercise Price \| $ / shares	$ 4.71
Expiration Date	Dec. 31, 2022
Options Thirteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options \| shares	10,420
Exercise Price \| $ / shares	$ 10.40
Expiration Date	Jun. 30, 2023
Options Fourteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options \| shares	16,000
Exercise Price \| $ / shares	$ 12.49
Expiration Date	Aug. 13, 2023
Options Fiveteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options \| shares	6,000
Exercise Price \| $ / shares	$ 12.51
Expiration Date	Aug. 20, 2023
Options Sixteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options \| shares	10,000
Exercise Price \| $ / shares	$ 12.70
Expiration Date	Aug. 22, 2023
Options Seventeen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options \| shares	15,000
Exercise Price \| $ / shares	$ 12.73
Expiration Date	Sep. 04, 2023
Options Eighteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options \| shares	125,000
Exercise Price \| $ / shares	$ 15.40
Expiration Date	Oct. 16, 2023
Options Nineteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options \| shares	7,000
Exercise Price \| $ / shares	$ 16.24
Expiration Date	Oct. 22, 2023
Options Twenty [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options \| shares	1,554,700
Exercise Price \| $ / shares	$ 4.63

Stock Options (Details Textual) - USD ($)	12 Months Ended
Stock Options (Details Textual) - USD ($)	Dec. 31, 2018	Dec. 31, 2017	May 14, 2018
Stock Options (Textual)
Restricted shares	130,001
Shares issued			908
Compensation cost	$ 1,317,904	$ 815,014
Expense remaining to be recognized related to options	$ 1,433,198
Stock options are exercisable term	10 years
Stock Compensation Plan [Member]
Stock Options (Textual)
Shares reserved for issuance	500,000
Share-based compensation plan, description	The Plan was amended in 2016 to increase the authorized shares to 1,333,334 shares, again in 2018 to increase the authorized shares to 1,833,334, and again in 2019 to increase the authorized shares to 2,500,000.
Options outstanding	1,554,700
Non-vested shares	513,167
Weighted average contractual life	2 years 9 months 18 days
Options exercisable	1,041,533
Stock Options [Member]
Stock Options (Textual)
Weighted average contractual life	2 years 9 months 18 days
Options exercisable	1,041,533
Options Nine [Member]
Stock Options (Textual)
Options expired	Mar. 03, 2019
Options Eight [Member]
Stock Options (Textual)
Options expired	Nov. 01, 2022
Options Seven [Member]
Stock Options (Textual)
Options expired	Jul. 28, 2021
Options Six [Member]
Stock Options (Textual)
Options expired	Feb. 22, 2021
Options One [Member]
Stock Options (Textual)
Options expired	Mar. 31, 2022
Options Two [Member]
Stock Options (Textual)
Options expired	Mar. 17, 2019
Options Three [Member]
Stock Options (Textual)
Options expired	May 19, 2019
Options Four [Member]
Stock Options (Textual)
Options expired	Jun. 24, 2020
Options Five [Member]
Stock Options (Textual)
Options expired	Jul. 27, 2022

Warrants (Details) - Warrant [Member] - $ / shares	12 Months Ended
Warrants (Details) - Warrant [Member] - $ / shares	Dec. 31, 2018	Dec. 31, 2017
Number of Shares Underlying Warrants
Beginning balance	348,194	681,527
Expired	(348,194)	(333,333)
Ending balance		348,194
Weighted average exercise price
Beginning Balance	$ 3.33	$ 5.01
Expired		6.75
Ending Balance		$ 3.33

Major Customers and Vendors (Details) - USD ($)	12 Months Ended
Major Customers and Vendors (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Revenue, Major Customer [Line Items]
Revenue	$ 21,206,363	$ 12,127,422
Customer A [Member]
Revenue, Major Customer [Line Items]
Revenue	$ 2,547,113	$ 957,222
Revenue Percentage	12.00%	7.90%
Customer B [Member]
Revenue, Major Customer [Line Items]
Revenue	$ 2,280,873	$ 1,422,072
Revenue Percentage	10.80%	11.70%
Customer C [Member]
Revenue, Major Customer [Line Items]
Revenue	$ 2,122,657	$ 1,153,714
Revenue Percentage	10.00%	9.50%
Partner A [Member]
Revenue, Major Customer [Line Items]
Revenue	$ 6,841,386	$ 3,901,811
Revenue Percentage	32.30%	32.20%
Partner B[Member]
Revenue, Major Customer [Line Items]
Revenue	$ 5,350,393	$ 2,047,238
Revenue Percentage	25.20%	16.90%
Partner C [Member]
Revenue, Major Customer [Line Items]
Revenue	$ 2,584,103	$ 1,231,662
Revenue Percentage	12.20%	10.20%
Partner D [Member]
Revenue, Major Customer [Line Items]
Revenue	$ 2,159,356	$ 1,279,321
Revenue Percentage	10.20%	10.50%

Major Customers and Vendors (Details Textual) - Revenue [Member]	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Four Key Partners [Member]
Revenue, Major Customer [Line Items]
Concentration Risk Percentage Total	10.00%	10.00%
Customer [Member]
Revenue, Major Customer [Line Items]
Concentration Risk Percentage Total	10.00%	10.00%
Other Customer [Member]
Revenue, Major Customer [Line Items]
Concentration Risk Percentage Total	10.00%

Income Taxes (Details) - USD ($)	12 Months Ended
Income Taxes (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Federal income tax benefit attributable to:
Current operations	$ (48,000)	$ 715,000
Permanent and timing differences (net)	(36,000)	(280,000)
Tax rate change		(1,600,000)
Valuation allowance	84,000	1,165,000
Net provision for federal income tax

Income Taxes (Details 1) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Deferred tax asset attributable to:
Net operating loss carryover	$ 2,290,000	$ 2,551,000
Depreciation and amortization	119,000	98,000
Stock compensation	535,000	372,000
Other	(6,000)
Valuation allowance	(2,938,000)	(3,021,000)
Net deferred tax asset

Income Taxes (Details Textual) - USD ($)	12 Months Ended
Income Taxes (Details Textual) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Income Taxes (Textual)
Operating loss carryforwards	$ 10,900,000
Operating loss expire, description	Expire from 2027 through 2037 that are available to offset future taxable income.
Effective rate of tax expected	21.00%	21.00%
Minimum [Member]
Income Taxes (Textual)
Statutory federal income tax rate	21.00%
Maximum [Member]
Income Taxes (Textual)
Statutory federal income tax rate	35.00%

Commitments and Contingent Liabilities (Details)	Dec. 31, 2018 USD ($)
Year ended December 31:
2019	$ 76,104
Total lease commitment	$ 76,104

Commitments and Contingent Liabilities (Details Textual) - USD ($)	1 Months Ended	3 Months Ended	12 Months Ended
	Jul. 04, 2018	Mar. 31, 2018	Dec. 31, 2018
Commitments and Contingent Liabilities (Textual)
Contingent Liabilities related to audit fees in percentage			10.00%
Description of new leasing arrangements			The current lease is a three-year lease beginning December 1, 2016, with options for up to an additional 6 years. The rent is payable monthly at rates of $6,232, $6,308, and $6,384 per month for years 1, 2, and 3 of the lease, respectively. The monthly rates for the option years range from $6,384 per month to $6,688 per month for the option years 4 through 9 of the lease. If the Company fails to exercise its option for option years 4 and 5, a lease termination payment of $7,300 will be due at the end of the initial 3-year term.
Lease expiration date			Nov. 30, 2016
New Jersey [Member]
Commitments and Contingent Liabilities (Textual)
Operating lease payable		$ 700
Croatia [Member]
Commitments and Contingent Liabilities (Textual)
Operating lease payable	$ 630
Nashville [Member]
Commitments and Contingent Liabilities (Textual)
Operating lease payable			$ 2,050

Retirement Plan (Details) - USD ($)	12 Months Ended
Retirement Plan (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Retirement Benefits [Abstract]
Defined benefit plan, description	The terms of the plan, the Company matches 100% of the first 3% of payroll contributed by the employee and 50% of the next 2% of payroll contributed by the employee to a maximum of 4% of an employee's payroll.
Defined contribution plan, administrative expense	$ 172,107	$ 137,858

Subsequent Events (Details) - USD ($)	1 Months Ended			12 Months Ended
Subsequent Events (Details) - USD ($)	Feb. 28, 2019	Feb. 01, 2019	Jan. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Subsequent Events (Textual)
Shares Issued				12,038,618	9,772,694
Proceeds from issuance of shares				$ 8,164,475
Subsequent Event [Member]
Subsequent Events (Textual)
Shares Issued			56,493
Proceeds from issuance of shares			$ 228,386
Subsequent Event [Member] \| New Jersey [Member]
Subsequent Events (Textual)
Lease Term		3 years
Subsequent Event [Member] \| New Jersey [Member] \| Minimum [Member]
Subsequent Events (Textual)
Lease payments		$ 2,707
Subsequent Event [Member] \| New Jersey [Member] \| Maximum [Member]
Subsequent Events (Textual)
Lease payments		$ 2,808
Subsequent Event [Member] \| Directors [Member]
Subsequent Events (Textual)
Number of shares authorized increased	2,500,000
Restricted common stock to officers	50,000
Options to purchase of common stock	67,050
Options to purchase, exercise price	13.06
Existing options that previously vested, description	The Company granted 35,500 time-based options, with the same exercise price, to new employees, as well as accelerated vesting to 2019 on 100,000 existing options that previously vested in 2020.